MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202621070856 A) filed by School Of Pharmaceutical Sciences, Lnct University, Bhopal on June 07, 2026, for A Novel Polymeric Transdermal Drug Delivery System Comprising Remogliflozin Etabonate For Sustained Antidiabetic Therapy.
Inventors include Ms. Ayushi Jain; and Dr. Akhlesh Kumar Singhai.
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: The present invention relates to a polymeric transdermal drug delivery system comprising Remogliflozin Etabonate for sustained management of diabetes mellitus. The transdermal patch comprises a combination of hydroxypropyl methylcellulose, Eudragit RLPO, Eudragit RSPO, a polyvinyl alcohol backing membrane, and a plasticizer for regulating drug release and maintaining structural integrity. The patch is prepared by a solvent casting and evaporation process to obtain a flexible film suitable for prolonged skin application. Formulation variables are optimized using a Box–Behnken experimental design to achieve controlled physicochemical characteristics and sustained drug release. The developed system enables transdermal permeation of Remogliflozin Etabonate over an extended period. In vivo evaluation in streptozotocin-induced diabetic animals demonstrates effective glycemic control and improvement in associated biochemical parameters. The invention provides a sustained-release transdermal therapeutic system for long-term antidiabetic treatment.
Disclaimer: Curated by HT Syndication.
